# Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

Study · id `cardio:ct-nct02922036` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02922036](<https://clinicaltrials.gov/study/NCT02922036>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02922036

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT02922036. Allocation not applicable; no masking; primary purpose treatment. Start 2018-01-17 (actual); primary completion 2027-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT02922036, source copy `cardio:ctgov-nct02922036-2026-10-16`, retrieved 2026-10-26)
- Started: 2018-01-17 (actual) (ClinicalTrials.gov record NCT02922036, source copy `cardio:ctgov-nct02922036-2026-10-16`, retrieved 2026-10-26)
- Primary completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT02922036, source copy `cardio:ctgov-nct02922036-2026-10-16`, retrieved 2026-10-26)
- Completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT02922036, source copy `cardio:ctgov-nct02922036-2026-10-16`, retrieved 2026-10-26)
- Countries: United States; Australia; France; Germany; Italy; Netherlands; United Kingdom (ClinicalTrials.gov record NCT02922036, source copy `cardio:ctgov-nct02922036-2026-10-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02922036-2026-10-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients
- Acronym: SOLVE-CRT
- Condition: Heart Failure
- Intervention (Device): WiSE System
- Lead sponsor: EBR Systems, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 7af569f434fb876a26ce4153c6e8b4c704517e219aedf19e3101c50947bf28dc
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
